[go: up one dir, main page]

WO2021230677A1 - Nouveau composé polyphénol et composition antifongique contenant celui-ci en tant que principe actif - Google Patents

Nouveau composé polyphénol et composition antifongique contenant celui-ci en tant que principe actif Download PDF

Info

Publication number
WO2021230677A1
WO2021230677A1 PCT/KR2021/006006 KR2021006006W WO2021230677A1 WO 2021230677 A1 WO2021230677 A1 WO 2021230677A1 KR 2021006006 W KR2021006006 W KR 2021006006W WO 2021230677 A1 WO2021230677 A1 WO 2021230677A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
antifungal
acid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/006006
Other languages
English (en)
Korean (ko)
Inventor
김기현
정원희
류제식
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University
Industry Academic Cooperation Foundation of Chung Ang University
Original Assignee
Sungkyunkwan University
Industry Academic Cooperation Foundation of Chung Ang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210061575A external-priority patent/KR20210141386A/ko
Application filed by Sungkyunkwan University, Industry Academic Cooperation Foundation of Chung Ang University filed Critical Sungkyunkwan University
Publication of WO2021230677A1 publication Critical patent/WO2021230677A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones

Definitions

  • the present invention relates to a novel compound and an antifungal composition containing the same as an active ingredient.
  • Fungus refers to a group of microorganisms including mold, yeast, and mushrooms. Most of them cannot synthesize nutrients themselves, so they live as parasites on other organisms. In humans, most of the infections are on the skin, such as the scalp, hair, face, arms, legs, nails or toenails, where a lot of dead and peeling cells are distributed, but it can also be infected with the gastrointestinal mucosa or vaginal mucosa, and it can cause systemic infection by infection with internal organs, etc. also cause On the other hand, fungal infections are caused by immunodeficiency, old age, use of immunosuppressants or steroids, nutritional deficiencies, poor hygiene, and contact with infected patients.
  • An antifungal agent refers to a substance for preventing or treating symptoms caused by a fungal infection by inhibiting the growth or reproduction of fungi.
  • Fungal infectious diseases in humans and animals can be broadly divided into systemic mycosis and epidermal mycosis according to the location of the infected tissue. Among them, systemic mycosis rarely causes disease in healthy people, but is often caused by opportunistic infections in people with weakened immunity. ), and aspergillosis.
  • Cryptococcosis is caused by infection with Cryptococcus neoformans and infects all parts of the body including the skin in patients with weakened immunity such as AIDS patients, especially the brain and meninges. infection, leading to meningitis, brain abscesses and brain tumors.
  • Candidasis is a mycosis caused by Candida albicans and was first isolated from thrush patients and causes vaginitis in women and diaper rash in infants.
  • Ringworm is a skin disease caused by Trichophyton such as Trichophyton rubrum and Trichophyton mentagrophytes. It is known to cause skin lesions.
  • antifungal agents have disadvantages in that they are toxic, a narrow activity range, and a fungistatic rather than a fungicide. Some of these also exhibit drug-drug interactions, resulting in very complex treatment. According to the recent trend in which a lot of fungal infections occur in immunosuppressed patients and the patient population is steadily increasing, there is an increasing demand for new antifungal agents having broad-spectrum activity and excellent pharmacological properties.
  • an object of the present invention is to provide a compound having at least one chemical formula selected from the group consisting of the following Chemical Formulas 1 to 3, or a salt thereof.
  • Another object of the present invention is to extract (a) Woodpodia uniflora with water or an organic solvent having 1 to 4 carbon atoms;
  • step (b) fractionating the extract obtained in step (a) with ethyl-acetate or butyl alcohol;
  • step (c) to provide a method for preparing the compound comprising the step of separating and purifying the fraction obtained in step (b) by gradient chromatography.
  • Another object of the present invention is to provide an antifungal composition
  • an antifungal composition comprising a compound of Formula 4 or Formula 5 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the R 1 To R 3 are each independently H, OH, C 1 to C 3 alkyl, C 1 to C 3 alkoxy, gallic acid, or heterocycloalkyl;
  • R 4 and R 7 are each independently H, O, OH, C 1 to C 3 alkyl group, C 1 to C 3 alkoxy group, O-gallic acid, O- glucose, O-rhamnose, O-Glucogalic acid, or ego,
  • R 8 and R 9 are each independently H, OH, O- gallic acid, C 1 to C 3 alkyl, C 1 to C 3 alkoxy;
  • the R 5 and R 6 are single or double bonded to each other to form a ring structure.
  • X or Y is each independently H, methyl or ethyl.
  • Another object of the present invention is to provide an antifungal composition
  • an antifungal composition comprising a Woodpodia uniflora extract or a fraction thereof as an active ingredient.
  • the present invention provides a compound having at least one chemical formula selected from the group consisting of the following Chemical Formulas 1 to 3, or a salt thereof.
  • the present invention comprises the steps of (a) extracting Woodpodia uniflora with water or an organic solvent having 1 to 4 carbon atoms;
  • step (b) fractionating the extract obtained in step (a) with ethyl-acetate or butyl alcohol;
  • step (c) provides a method for preparing the compound comprising the step of separating and purifying the fraction obtained in step (b) by gradient chromatography.
  • the present invention provides an antifungal composition
  • the R 1 To R 3 are each independently H, OH, C 1 to C 3 alkyl, C 1 to C 3 alkoxy, gallic acid, or heterocycloalkyl;
  • R 4 and R 7 are each independently H, O, OH, C 1 to C 3 alkyl group, C 1 to C 3 alkoxy group, O-gallic acid, O-glucose, O-rhamnose, O-Glucogalic acid, or ego,
  • R 8 and R 9 are each independently H, OH, O- gallic acid, C 1 to C 3 alkyl, C 1 to C 3 alkoxy;
  • the R 5 and R 6 are single or double bonded to each other to form a ring structure.
  • X or Y is each independently H, methyl or ethyl.
  • the present invention provides an antifungal composition
  • the compound may be isolated from Woodfordia uniflora or a culture thereof, but is not limited thereto.
  • the compound may have an antifungal effect, but is not limited thereto.
  • the organic solvent of step (a) is methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, dichloromethane and petroleum ether It may be one or more selected from the group consisting of, but is not limited thereto.
  • the antifungal composition has antifungal activity against at least one selected from the group consisting of Candida spp. , Cryptococcus spp. , and Trichophyton spp. may have, but is not limited thereto.
  • the compound of Formula 4 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 1 is H or OH
  • R 2 is H, methoxy, methyl, ethyl, gallic acid or ego,
  • R 3 is H or OH
  • R 4 is H, O or ego
  • the R 7 is , OH, O-rhamnosus, or O-gallic acid,
  • the R 5 and R 6 may be single or double bonded to each other to form a ring structure, but is not limited thereto.
  • the compound of Formula 4 may be represented by the following Formula 6, but is not limited thereto.
  • R 2 is H, gallic acid, or ego
  • R 4 is H or ego
  • R 7 is H, OH or gallic acid.
  • the compound of Formula 5 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Y may be methyl, but is not limited thereto.
  • the compound of Formula 4 is woodfordiamycin, (+)-catechin 7-O-gallate ((+)-catechin7-O-gallate) and procyanidin B3-3 It may be one selected from the group consisting of -O-gallate (procyanidin B3-3- O-gallate), but is not limited thereto.
  • the extract may be an extract using water or an organic solvent having 1 to 4 carbon atoms, but is not limited thereto.
  • the fraction may be obtained by fractionation with ethyl acetate or n-butanol, but is not limited thereto.
  • the present invention also provides an antifungal method comprising administering to a subject a composition comprising the compound of Formula 4 or Formula 5 or a pharmaceutically acceptable salt thereof.
  • the antifungal method may be a method of treating a fungal infection.
  • the present invention provides an antifungal use of the compound of Formula 4 or Formula 5 or a pharmaceutically acceptable salt thereof.
  • the present invention provides the use of the compound of Formula 4 or Formula 5 or a pharmaceutically acceptable salt thereof for the preparation of an antifungal agent.
  • the present invention provides an antifungal method, comprising administering to a subject a composition comprising the Woodpodia uniflora extract or a fraction thereof.
  • the antifungal method may be a method of treating a fungal infection.
  • the present invention provides an antifungal use of a composition comprising an extract of Woodpodia uniflora or a fraction thereof.
  • the present invention provides the use of an extract of Woodpodia uniflora or a fraction thereof for the preparation of an antifungal agent.
  • the compounds of the present invention have excellent antifungal activity and can be usefully used as antifungal compositions.
  • 1 is a structural formula for 19 compounds isolated and purified from Woodfordia uniflora.
  • the present inventors have discovered compounds having excellent antifungal effects, and have completed the present invention.
  • the present invention provides a compound having at least one chemical formula selected from the group consisting of the following Chemical Formulas 1 to 3, or a salt thereof.
  • a compound having a chemical formula selected from the group consisting of Chemical Formulas 1 to 3 was first identified by the present inventors, and this is well shown in Examples of the present specification.
  • the compound of Formula 1 may be named woodfordiamycin by the present inventors, and 2-(3,4-dihydroxyphenyl)-5-hydroxychroman-7-yl 3,4,5- It can have the IUPAC name of trihydroxybenzoate.
  • the compound of Formula 2 may be named wood capsule diksan (woodfordic acid) by the present inventors, (S) -4-oxo- 3 - ((2 R, 3 S) -3,5, It may have the IUPAC name of 7-trihydroxychroman-2-yl)pentanoic acid.
  • the compound of Formula 3 is rhamnetin 3-O-(6′′-galloyl)- ⁇ -glucopyranoside (rhamnetin 3-O-(6′′-galloyl)- ⁇ -glucopyranoside).
  • rhamnetin 3-O-(6′′-galloyl)- ⁇ -glucopyranoside can be named ((2 R ,3 S ,4 S ,5 R ,6 S )-6-((2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-4-oxo-4 H- chromen-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2 H- pyran-2-yl)methyl 3,4,5-trihydroxybenzoate may have the IUPAC name.
  • the compound may be one isolated from Woodfordia uniflora or a culture thereof, but is not limited thereto.
  • the compound may have an antifungal effect, but is not limited thereto.
  • the compounds may have non-aromatic double bonds and one or more asymmetric centers. Thus, they may occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures and cis- or trans-isomers. All such isomeric forms are contemplated.
  • the present invention may include a derivative compound such as a hydrate of a compound represented by a formula selected from the group consisting of Chemical Formulas 1 to 3 or a glycoside in which a compound such as a sugar is bonded to each side chain.
  • a derivative compound such as a hydrate of a compound represented by a formula selected from the group consisting of Chemical Formulas 1 to 3 or a glycoside in which a compound such as a sugar is bonded to each side chain.
  • the compound according to the present invention can be isolated from nature or prepared by chemical synthesis of compounds known in the art.
  • the compounds of the present invention can be isolated and purified from natural plants. That is, it can be obtained from a plant or a part of a plant using a conventional method for extracting and isolating a substance. Stems, roots or leaves are properly dried and macerated to obtain the desired extract, or simply dried and extracted with an appropriate organic solvent, and the desired extract is purified using a purification method known to those skilled in the art to which the present invention pertains. can be purified.
  • the compound of the present invention can be isolated and purified from Woodfordia uniflora or a culture thereof.
  • the term "culture” refers to the culture medium in which Woodfordia uniflora according to the present invention is cultured in a suitable liquid medium, the culture medium is filtered or centrifuged to remove the strain (filtrate) or centrifuged supernatant), and a cell lysate obtained by sonicating the culture solution or treating the culture solution with a lysozyme, preferably means a supernatant after centrifugation, but is limited thereto no.
  • the culture solution may include both a concentrated solution of the culture solution and a dried product of the culture solution.
  • the present invention comprises the steps of (a) extracting Woodpodia uniflora with water or an organic solvent having 1 to 4 carbon atoms;
  • step (b) fractionating the extract obtained in step (a) with ethyl-acetate or butyl alcohol;
  • step (c) provides a method for preparing the compound comprising the step of separating and purifying the fraction obtained in step (b) by gradient chromatography.
  • the whole Woodpodia uniflora plant, leaves, stems, and roots may be used as they are or their dried bodies may be used, and those obtained by pulverizing the dried plants with a grinder may be used to increase extraction efficiency.
  • a drying method both dry drying, shade drying, hot air drying, freeze drying, and natural drying methods can be used.
  • the organic solvent having 1 to 4 carbon atoms used for the Woodpodia Uniflora extraction is methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, dichloromethane or petroleum ether.
  • Woodpodia uniflora was extracted with ethanol, methanol, or acetone.
  • step (b) the extract obtained in step (a) is fractionated, followed by distribution extraction using ethyl-acetate or butyl alcohol.
  • the fraction obtained in step (b) is separated by gradient chromatography.
  • column chromatography or high performance liquid chromatography (HPLC) filled with various synthetic resins such as silica gel or activated alumina can be used alone or in combination.
  • HPLC high performance liquid chromatography
  • an ethyl-acetate fraction or a butyl alcohol fraction is applied to a silica gel column, and various fractions can be obtained while gradually increasing the polarity by adjusting the composition of the elution solvent.
  • Concentration gradient silica gel chromatography in which the polarity is gradually increased by adjusting the composition of the elution solvent again to the active fraction among the fractions obtained in the above process can be performed.
  • the method for extraction and separation and purification of the compound is not necessarily limited to the above method.
  • step (c) the ethyl-acetate fraction obtained in step (b) is separated and purified by gradient chromatography.
  • chromatography column chromatography filled with various synthetic resins such as silica gel or activated alumina and high performance liquid chromatography (HPLC) can be used alone or in combination.
  • HPLC high performance liquid chromatography
  • the compound can be separated and purified using high-performance liquid chromatography.
  • the present invention provides an antifungal composition
  • the R 1 To R 3 are each independently H, OH, C 1 to C 3 alkyl, C 1 to C 3 alkoxy, gallic acid, or heterocycloalkyl;
  • R 4 and R 7 are each independently H, O, OH, C 1 to C 3 alkyl group, C 1 to C 3 alkoxy group, O-gallic acid, O-glucose, O-rhamnose, O-Glucogalic acid, or ego,
  • R 8 and R 9 are each independently H, OH, O- gallic acid, C 1 to C 3 alkyl, C 1 to C 3 alkoxy;
  • the R 5 and R 6 are single or double bonded to each other to form a ring structure.
  • X or Y is each independently H, methyl or ethyl.
  • R 1 is H or OH
  • R 2 is H, methoxy, methyl, ethyl, gallic acid or ego,
  • R 3 is H or OH
  • R 4 is H, O or ego
  • the R 5 and R 6 may be single or double bonded to each other to form a ring structure, but is not limited thereto.
  • the compound of Chemical Formula 4 may be one represented by the following Chemical Formula 6, but is not limited thereto.
  • R 2 is H, gallic acid, or ego
  • R 4 is H or ego
  • R 7 is H, OH or gallic acid.
  • Y may be methyl, but is not limited thereto.
  • the compound may be named IUPAC name listed in the table below, but is not limited thereto.
  • the compound of Formula 4 is woodfordiamycin, (+)-catechin 7-O-gallate ((+)-catechin7-O-gallate) and procyanidin B3-3-O-gallate.
  • procyanidin B3-3- O- gallate may be at least one selected from the group consisting of, but is not limited thereto.
  • the compound of Formula 4 or 5 may be isolated and purified from Woodpodia uniflora, or may be prepared by a chemical synthesis method known in the art.
  • the compounds of the present invention can be extracted from Woodpodia uniflora.
  • the compound may be extracted from Woodpodia uniflora by a known method commonly used in the art, such as organic solvent extraction and chromatography.
  • the present invention provides an antifungal composition
  • the extract may be an extract using water or an organic solvent having 1 to 4 carbon atoms, but is not limited thereto.
  • the organic solvent having 1 to 4 carbon atoms used for the Woodpodia uniflora extraction is methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, dichloromethane or petroleum ether.
  • Woodpodia uniflora was extracted with ethanol, methanol, or acetone.
  • Woodpodia uniflora of the present invention can be used as it is without damaging its original form, or after performing a pretreatment process in consideration of the process speed and process (manufacturing) efficiency intended by those skilled in the art, the pretreatment process includes examples For example, it may be subjected to conventional screening, washing, cutting, powdering, drying, and the like steps.
  • the Woodpodia uniflora extract of the present invention can be obtained from the whole plant or a part of a plant, for example, it can be obtained from a site comprising one or more selected from the group consisting of stems, roots, leaves, fruits, and flowers. have.
  • Woodpodia uniflora of the present invention can be used by conventional extraction methods such as cold chim, warm chim, and heating using the solvent.
  • the fraction may be obtained by fractionation with ethyl acetate or n-butanol, but is not limited thereto.
  • the antifungal composition may have antifungal activity against one or more selected from the group consisting of Candida spp. , Cryptococcus spp. , and Trichophyton spp. , but is not limited thereto.
  • the antifungal composition is for treating a fungal infection caused by one or more fungi selected from the group consisting of Candida spp. , Cryptococcus spp. , and Trichophyton spp. It may be used, but is not limited thereto.
  • the fungal infection includes, for example, cryptococcosis, candidasis, ringworm (trichophytosis), aspergillosis, and the like, but is not limited thereto.
  • Cryptococcosis is caused by infection with Cryptococcus neoformans and infects all parts of the body including the skin in patients with weakened immunity such as AIDS patients, especially the brain and meninges. infection, leading to meningitis, brain abscesses and brain tumors.
  • Candidasis is a mycosis caused by Candida albicans and was first isolated from thrush patients and causes vaginitis in women and diaper rash in infants.
  • Ringworm is a skin disease caused by Trichophyton such as Trichophyton rubrum and Trichophyton mentagrophytes. This causes skin lesions.
  • the composition may be a pharmaceutical composition, a food composition or a cosmetic composition, but is not limited thereto.
  • the present invention may also include a pharmaceutically acceptable salt of the compound of Formula 4 or 5 as an active ingredient.
  • pharmaceutically acceptable salt includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases.
  • acids examples include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , benzoic acid, malonic acid, gluconic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Acid addition salts can be prepared by conventional methods, for example, by dissolving a compound in an aqueous solution of an excess of acid, and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. It can also be prepared by heating an equimolar amount of the compound and an acid or alcohol in water and then evaporating the mixture to dryness, or by suction filtration of the precipitated salt.
  • a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
  • Salts derived from suitable bases may include, but are not limited to, alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium.
  • the alkali metal or alkaline earth metal salt can be obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate.
  • a suitable silver salt eg, silver nitrate
  • the content of the compound of Formula 4 or 5 in the composition of the present invention can be appropriately adjusted depending on the symptoms of the disease, the degree of progression of the symptoms, the condition of the patient, etc., for example, 0.0001 to 99.9 wt%, or 0.001, based on the total weight of the composition to 50% by weight, but is not limited thereto.
  • the content ratio is a value based on the dry amount from which the solvent is removed.
  • the pharmaceutical composition according to the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
  • the excipient may be, for example, at least one selected from the group consisting of a diluent, a binder, a disintegrant, a lubricant, an adsorbent, a humectant, a film-coating material, and a controlled-release additive.
  • the pharmaceutical composition according to the present invention can be prepared according to a conventional method, respectively, in powders, granules, sustained-release granules, enteric granules, liquids, eye drops, elsilic, emulsions, suspensions, spirits, troches, fragrances, and limonaade.
  • tablets, sustained release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, perfusates, Warnings, lotions, pastas, sprays, inhalants, patches, sterile injection solutions, or external preparations such as aerosols can be formulated and used, and the external preparations are creams, gels, patches, sprays, ointments, warning agents , lotion, liniment, pasta, or cataplasma.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • water diluted hydrochloric acid, diluted sulfuric acid, sodium citrate, monostearate sucrose, polyoxyethylene sorbitol fatty acid esters (Twinester), polyoxyethylene monoalkyl ethers, lanolin ethers, Lanolin esters, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, and the like can be used.
  • sucrose solution other sugars or sweeteners may be used, and if necessary, a fragrance, colorant, preservative, stabilizer, suspending agent, emulsifier, thickening agent, etc. may be used.
  • Purified water may be used in the emulsion according to the present invention, and if necessary, an emulsifier, preservative, stabilizer, fragrance, etc. may be used.
  • Suspending agents such as acacia, tragacantha, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, HPMC 2910 may be used in the suspending agent according to the present invention. and, if necessary, surfactants, preservatives, stabilizers, colorants, and fragrances may be used.
  • the injection according to the present invention includes distilled water for injection, 0.9% sodium chloride injection solution, ring gel injection solution, dextrose injection solution, dextrose + sodium chloride injection solution, PEG (PEG), lactated ring gel injection solution, ethanol, propylene glycol, non-volatile oil-sesame oil , solvents such as cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; Solubilizing aids such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, tweens, nijeongtinamide, hexamine, and dimethylacetamide; Weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, buffers such as albumin
  • the suppository according to the present invention includes cacao fat, lanolin, witepsol, polyethylene glycol, glycerogelatin, methyl cellulose, carboxymethyl cellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cacao butter + Cholesterol, Lecithin, Lanet Wax, Glycerol Monostearate, Tween or Span, Imhausen, Monolene (Propylene Glycol Monostearate), Glycerin, Adeps Solidus, Butyrum Tego -G), Cebes Pharma 16, Hexalide Base 95, Cotomar, Hydroxote SP, S-70-XXA, S-70-XX75 (S-70-XX95), Hydro Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium, A, AS, B, C, D, E, I, T, Massa-MF, Masupol, Masupol-15, Neos
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the extract, for example, starch, calcium carbonate, sucrose ) or lactose, gelatin, etc.
  • excipients for example, starch, calcium carbonate, sucrose ) or lactose, gelatin, etc.
  • lubricants such as magnesium stearate talc are also used.
  • Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • composition according to the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, drug activity, and type of the patient's disease; Sensitivity to the drug, administration time, administration route and excretion rate, treatment period, factors including concurrent drugs and other factors well known in the medical field may be determined.
  • the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by a person skilled in the art to which the present invention pertains.
  • the pharmaceutical composition of the present invention may be administered to an individual by various routes. All modes of administration can be envisaged, for example, oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal (intrathecal) injection, sublingual administration, buccal administration, rectal insertion, vaginal It can be administered according to internal insertion, ocular administration, ear administration, nasal administration, inhalation, spraying through the mouth or nose, skin administration, transdermal administration, and the like.
  • the pharmaceutical composition of the present invention is determined according to the type of drug as the active ingredient along with various related factors such as the disease to be treated, the route of administration, the patient's age, sex, weight, and the severity of the disease.
  • “individual” means a subject in need of treatment for a disease, and more specifically, human or non-human primates, mice, rats, dogs, cats, horses, cattle, etc. It may be a mammal of, but is not limited thereto.
  • administration means providing a predetermined composition of the present invention to an individual by any suitable method.
  • prevention means any action that suppresses or delays the onset of a target disease
  • treatment means that the target disease and its metabolic abnormalities are improved or It means any action that is advantageously changed
  • improvement means any action that reduces a parameter related to a desired disease, for example, the degree of a symptom by administration of the composition according to the present invention.
  • composition of the present invention may be provided in the form of a quasi-drug composition.
  • the quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent if necessary in addition to the above components.
  • a pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not affect the effect of the present invention, and for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a fragrance, a preservative. and the like.
  • acceptable carriers, excipients or diluents for the quasi-drug composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia gum, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , injectable esters, Witepsol, Macrogol, Tween 61, cacao butter, laurage, and the like.
  • the quasi-drug composition of the present invention may include, but is not limited to, disinfection cleaner, shower foam, ointment, wet tissue, coating agent, etc. It may be appropriately selected from the techniques of
  • composition of the present invention may be provided in the form of a food composition.
  • the compound of Formula 4 or 5 of the present invention When the compound of Formula 4 or 5 of the present invention is used as a food additive, the compound of Formula 4 or 5 may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the compound of Formula 4 or 5 of the present invention when preparing food or beverage, the compound of Formula 4 or 5 of the present invention may be added in an amount of 15 wt% or less, or 10 wt% or less based on the raw material.
  • the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes, and includes all health functional foods in the ordinary sense.
  • the health beverage composition according to the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, as in a conventional beverage.
  • the above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • natural sweeteners such as taumatine and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used.
  • the proportion of the natural carbohydrate is generally about 0.01-0.20 g, or about 0.04-0.10 g per 100 mL of the composition of the present invention.
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may contain a carbonation agent used for carbonated beverages, and the like.
  • the composition of the present invention may contain fruit for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not critical, but is generally selected in the range of 0.01-0.20 parts by weight per 100 parts by weight of the composition of the present invention.
  • composition of the present invention may be provided in the form of a cosmetic composition.
  • the compound of Formula 4 or 5 of the present invention can be used as a cosmetic additive to prepare a cosmetic composition for keeping hands or feet clean.
  • soap solid soap, liquid soap, bounty soap, body soap, hand soap, etc.
  • cleansing foam for example, soap is preferable, and in particular, it can be used in formulations such as liquid soap and body soap.
  • the formulation of the cosmetic composition according to the present invention includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, mist, moisture cream, hand cream, hand lotion, foundation, It may be in the form of essence, nutritional essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, cleansing oil, cleansing balm, body lotion or body cleanser.
  • the cosmetic composition of the present invention may further include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, and sphingolipids.
  • water-soluble vitamins any one can be used as long as it can be formulated in cosmetics.
  • examples include vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, and vitamin H. and their salts (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-phosphate sodium salt, ascorbic acid-2-phosphate magnesium salt, etc.) are also included in the water-soluble vitamins that can be used in the present invention. Included. Water-soluble vitamins can be obtained by conventional methods such as a microbial transformation method, a purification method from a microbial culture, an enzymatic method or a chemical synthesis method.
  • the oil-soluble vitamins may be any as long as they can be formulated in cosmetics.
  • vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), etc. are mentioned.
  • Oil-soluble vitamins can be obtained by conventional methods such as a microbial transformation method, a purification method from a microbial culture, an enzyme or a chemical synthesis method, and the like.
  • the macromolecular peptide may be any as long as it can be formulated in cosmetics, and examples thereof include collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, and keratin.
  • Polymeric peptides can be purified and obtained by conventional methods such as purification from microbial culture, enzymatic methods or chemical synthesis, or can be purified and used from natural products such as dermis of pigs or cattle, silk fibers of silkworms, and the like.
  • the high molecular weight polysaccharide may be any compound as long as it can be formulated in cosmetics, and examples thereof include hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.).
  • chondroitin sulfate or a salt thereof can be used after purification from mammals or fish.
  • the sphingolipid may be any as long as it can be formulated in cosmetics, and examples thereof include ceramide, phytosphingosine, and sphingoglycolipid. Sphingo lipids can be purified by conventional methods from mammals, fish, shellfish, yeast or plants, or can be obtained by chemical synthesis.
  • composition of the present invention in addition to the above essential ingredients, other ingredients usually blended in cosmetics may be blended as needed.
  • oils and fats include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, A blood circulation promoter, a cooling agent, a restrictive agent, purified water, etc. are mentioned.
  • fat and oil component examples include ester fats and oils, hydrocarbon oils and fats, silicone oils and fats, fluorine oils and fats, animal oils and fats, and vegetable oils and fats.
  • ester-based oils and fats examples include glyceryl tri-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, stearic acid.
  • hydrocarbon-based fats and oils examples include hydrocarbon-based fats and oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybudene, microcrystalline wax, petrolatum.
  • silicone-based oils and fats examples include polymethyl silicone, methylphenyl silicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane/methylcetyloxysiloxane copolymer, dimethylsiloxane/methylstealloxysiloxane copolymer, and alkyl Modified silicone oil, amino modified silicone oil, etc. are mentioned.
  • Perfluoropolyether etc. are mentioned as fluorine-type fats and oils.
  • avocado oil avocado oil, almond oil, olive oil, sesame oil, rice bran oil, saffron oil, soybean oil, corn oil, rapeseed oil, passerine oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil , cottonseed oil, palm oil, kukui nut oil, wheat germ oil, rice germ oil, shea butter, cranberry colostrum, marcadeumia nut oil, meadow home oil, egg yolk oil, tallow oil, horse oil, mink oil, orange rafi oil, jojoba oil , animal or plant oils and fats, such as candelabra wax, carnauba wax, liquid lanolin, and hydrogenated castor oil.
  • avocado oil almond oil, olive oil, sesame oil, rice bran oil, saffron oil, soybean oil, corn oil, rapeseed oil, passerine oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil , cottonseed oil, palm oil, ku
  • humectant examples include a water-soluble low-molecular humectant, a fat-soluble molecular humectant, a water-soluble polymer, and a fat-soluble polymer.
  • Cholesterol, cholesterol ester, etc. are mentioned as a fat-soluble low molecular weight humectant.
  • water-soluble polymer examples include carboxyvinyl polymer, polyaspartate, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, and dextrin.
  • the fat-soluble polymer examples include polyvinylpyrrolidone/eicosene copolymer, polyvinylpyrrolidone/hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, and high molecular weight silicone.
  • emollient examples include long-chain acylglutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid, and lanolin fatty acid cholesteryl ester.
  • Nonionic surfactants anionic surfactants, cationic surfactants, amphoteric surfactants, etc. are mentioned as surfactant.
  • Nonionic surfactants include self-emulsifying glycerin monostearate, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerol fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbitan fatty acid ester, POE Glycerin fatty acid ester, POE alkyl ether, POE fatty acid ester, POE hydrogenated castor oil, POE castor oil, POE/POP (polyoxyethylene/polyoxypropylene) copolymer, POE/POP alkyl ether, polyether-modified silicone, lauric acid alkanolamides, alkylamine oxides, hydrogenated soybean phospholipids, and the like.
  • anionic surfactant examples include fatty acid soap, alpha-acyl sulfonate, alkyl sulfonate, alkyl allyl sulfonate, alkyl naphthalene sulfonate, alkyl sulfate, POE alkyl ether sulfate, alkyl amide sulfate, alkyl phosphate, POE alkyl phosphate, and alkyl amide phosphate.
  • alkyloyl alkyl taurine salt N-acyl amino acid salt
  • POE alkyl ether carboxylate salt alkyl sulfosuccinate salt, alkyl sulfoacetate sodium
  • acylated hydrolyzed collagen peptide salt perfluoroalkyl phosphate ester, etc.
  • cationic surfactant examples include alkyltrimethylammonium chloride, stearyltrimethylammonium chloride, stearyltrimethylammonium bromide, cetostearyltrimethylammonium chloride, distearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride, behenyltrimethylammonium bromide, chloride Benzalkonium, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salt of lanolin derivative, etc. are mentioned.
  • amphoteric surfactant examples include carboxybetaine type, amidebetaine type, sulfobetaine type, hydroxysulfobetaine type, amidesulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type, amidamine type, etc. Amphoteric surfactant etc. are mentioned.
  • organic and inorganic pigments include silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, bengala, clay, bentonite, titanium coated mica, bismuth oxychloride, zirconium oxide, magnesium oxide, zinc oxide, titanium oxide, aluminum oxide.
  • inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, ultramarine blue, chromium oxide, chromium hydroxide, calamine, and complexes thereof; Polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluororesin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, divinylbenzene/styrene copolymer, and organic pigments such as silk powder, cellulose, CI pigment yellow and CI pigment orange, and composite pigments of these inorganic pigments and organic pigments.
  • inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, ultramarine blue, chromium oxide, chromium hydroxide, calamine, and complexes thereof; Poly
  • organic powder examples include metal soaps such as calcium stearate; alkyl phosphate metal salts such as sodium cetylate, zinc laurylate, and calcium laurylate; acylamino acid polyvalent metal salts such as calcium N-lauroyl-beta-alanine, zinc N-lauroyl-beta-alanine, and calcium N-lauroyl glycine; amidesulfonic acid polyvalent metal salts such as calcium N-lauroyl-taurine and calcium N-palmitoyl-taurine; N such as N-epsilon-lauroyl-L-lysine, N-epsilon-palmitoylizine, N-alpha-paritoylolnithine, N-alpha-lauroylarginine, N-alpha-hydrogenated beef fatty acid acylarginine, etc.
  • metal soaps such as calcium stearate
  • alkyl phosphate metal salts such as
  • N-acyl polypeptides such as N-lauroyl glycyl glycine
  • alpha-amino fatty acids such as alpha-aminocaprylic acid and alpha-aminolauric acid
  • Polyethylene, polypropylene, nylon, polymethyl methacrylate, polystyrene, a divinylbenzene-styrene copolymer, ethylene tetrafluoride, etc. are mentioned.
  • UV absorbers para-aminobenzoic acid, ethyl para-aminobenzoate, amyl para-aminobenzoate, octyl para-aminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylate, benzyl cinnamate , para-methoxycinnamic acid-2-ethoxyethyl, para-methoxycinnamic acid octyl, dipara-methoxycinnamic acid mono-2-ethylhexaneglyceryl, para-methoxycinnamic acid isopropyl, diisopropyl diisopropyl cinnamic acid ester mixture, uro Cannic acid, ethyl urokanate, hydroxymethoxybenzophenone,
  • disinfectants include hinokitiol, triclosan, trichlorohydroxydiphenyl ether, chlorhexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, zinc phyllithione, benzalkonium chloride, photosensitizer. So, No. 301, mononitroguaial sodium, undecyrenic acid, etc. are mentioned.
  • antioxidant examples include butylhydroxyanisole, propyl gallic acid, and ellisorbic acid.
  • pH adjuster examples include citric acid, sodium citrate, malic acid, sodium malate, fmalic acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, and the like.
  • Examples of the alcohol include higher alcohols such as cetyl alcohol.
  • blending components that may be added are not limited thereto, and any of the above components can be blended within a range that does not impair the object and effect of the present invention, but 0.01-5% by weight or 0.01-3 based on the total weight. % by weight.
  • the formulation of the present invention is a lotion, paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. can be used
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.
  • a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.
  • the formulation of the present invention is a suspension
  • a carrier component water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
  • the formulation of the present invention is a surfactant-containing cleansing agent
  • Ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
  • the compound of Formula 4 or 5 can be used in various ways as antifungal building materials, pesticides, household goods additives, and the like, and can be used by mixing with known antifungal agents used in the field.
  • pesticide-related antifungal agents are described, for example, in the Pesticide Manual (Pesticide Manual, 12th ed., British Crop Protection Council, 2000).
  • the obtained crude extract was dissolved in 700 mL of tertiary distilled water, and solvent fractionation was performed with 700 mL of ethyl acetate and 700 mL of butyl alcohol, and as a result of concentration, 8.3 g of an ethyl acetate fraction and 1.5 g of a butyl alcohol fraction were obtained.
  • the two fractions showed antifungal effects against Cryptococcus neoformans and Candida albicans , and as a result of LC/MS analysis, there was no difference in components.
  • Diaion HP-20 column chromatography (0% methanol, 50% methanol, 100% methanol) was performed to obtain fractions W1 (2.0 g), W2 (2.5 g), and W3 (3.5 g). Then, in order to obtain a small fraction of the W3 fraction, Sephadex LH-20, silica gel column chromatography and column chromatography were performed using methanol and tertiary distilled water.
  • the obtained small fraction was subjected to high-performance liquid chromatography (HPLC) using acetonitrile and tertiary distilled water, and as a result, compounds 1-6 , 8 , 11 , 12 , 14 , 15 and 17 were separated by 13.2 mg, 3.0 mg, 2.5 mg, 1.2 mg, 6.9 mg, 1.3 mg, 1.5 mg, 1.5 mg, 1.6 mg, 4.2 mg, 8.5 mg, and 4.0 mg, respectively.
  • Sephadex LH-20, silica gel column chromatography and column chromatography were also performed for the W2 fraction, which is another fraction, using methanol and tertiary distilled water, thereby obtaining a small fraction of the W2 fraction.
  • Cryptococcus neoformans H99 was a Fluconazole
  • the activity was measured for the three fungi SC5314 used as positive control
  • Trichophyton rubrum KCTC6375 was used as positive control
  • Trichophyton activity measurement for two fungi mentagrophytes 784 has Itraconazole was used as a positive control.
  • compound 8 was also observed to have a MIC value of 0.78 ⁇ g/mL for C. neoformans , and higher activity than the positive control, Fluconazole, was confirmed.
  • the present invention relates to a novel compound derived from Woodpodia uniflora and an antifungal composition containing the same as an active ingredient, and the compound according to the present invention is characterized in that it has an excellent antifungal effect against various fungi.
  • the present inventors have confirmed that the compound according to the present invention has superior antifungal activity to fungi of the genus Candida, Cryptococcus, and Trichophyton, which is superior to that of conventional drugs for treating fungal infections. Accordingly, the compounds according to the present invention are expected to be usefully used in the treatment of diseases caused by various fungal infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau composé polyphénol et une composition antifongique contenant celui-ci en tant que principe actif. Le nouveau composé selon la présente invention a un excellent effet antifongique de sorte à être efficacement utilisable en tant que composition antifongique.
PCT/KR2021/006006 2020-05-14 2021-05-13 Nouveau composé polyphénol et composition antifongique contenant celui-ci en tant que principe actif Ceased WO2021230677A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20200057720 2020-05-14
KR10-2020-0057720 2020-05-14
KR10-2021-0061575 2021-05-12
KR1020210061575A KR20210141386A (ko) 2020-05-14 2021-05-12 신규 폴리페놀 화합물 및 이를 유효성분으로 함유하는 항진균용 조성물

Publications (1)

Publication Number Publication Date
WO2021230677A1 true WO2021230677A1 (fr) 2021-11-18

Family

ID=78524642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/006006 Ceased WO2021230677A1 (fr) 2020-05-14 2021-05-13 Nouveau composé polyphénol et composition antifongique contenant celui-ci en tant que principe actif

Country Status (2)

Country Link
KR (1) KR20250002059A (fr)
WO (1) WO2021230677A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894424A (zh) * 2023-01-06 2023-04-04 中日友好医院(中日友好临床医学研究所) 新型双黄酮类化合物及其制备方法、药物组合物和应用
WO2025082357A1 (fr) * 2023-10-16 2025-04-24 复旦大学 Composés polyphénoliques, leur procédé de préparation et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190133561A (ko) * 2018-05-23 2019-12-03 (주)에스디생명공학 유제놀 및 갈릭산을 유효성분으로 함유하는 항균 및 항진균 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101302678B1 (ko) 2012-09-18 2013-09-09 전라남도 동백나무 추출물을 유효성분으로 포함하는 항진균용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190133561A (ko) * 2018-05-23 2019-12-03 (주)에스디생명공학 유제놀 및 갈릭산을 유효성분으로 함유하는 항균 및 항진균 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABHISHEK R. U., MOHANA D. C., THIPPESWAMY S., MANJUNATH K.: "Evaluation of Phyllanthus polyphyllus L. Extract and its Active Constituent as a Source of Antifungal, Anti-Aflatoxigenic, and Antioxidant Activities", INTERNATIONAL JOURNAL OF FOOD PROPERTIES, MARCEL DEKKER, NEW YORK, NY, US, vol. 18, no. 3, 4 March 2015 (2015-03-04), US , pages 585 - 596, XP055866717, ISSN: 1094-2912, DOI: 10.1080/10942912.2013.853187 *
DE LEO, M.; BRACA, A.; DE TOMMASI, N.; NORSCIA, I. ; BATTINELLI, L.; MAZZANTI, G.: "Phenolic compounds from Baseonema acuminatum leaves: Isolation and antimicrobial activity", MEDICINAL & AROMATIC PLANTS ABSTRACTS, SCIENTIFIC PUBLISHERS, NEW DELHI - INDIA, 1 January 1901 (1901-01-01), Scientific Publishers, New Delhi - India , XP018000308 *
PARK BONG JOO, TAGUCHI HIDEAKI, KAMEI KATSUHIKO, MATSUZAWA TETSUHIRO, HYON SUONG-HYU, PARK JONG-CHUL: "In Vitro Antifungal Activity of Epigallocatechin 3- O -Gallate against Clinical Isolates of Dermatophytes", YONSEI MEDICAL JOURNAL, YONSEI UNIVERSITY, KI, vol. 52, no. 3, 1 January 2011 (2011-01-01), KI , pages 535 - 5796, XP055866721, ISSN: 0513-5796, DOI: 10.3349/ymj.2011.52.3.535 *
YU JAE SIK, PARK MINJI, PANG CHANGHYUN, RASHAN LUAY, JUNG WON HEE, KIM KI HYUN: "Antifungal Phenols from Woodfordia uniflora Collected in Oman", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 83, no. 7, 24 July 2020 (2020-07-24), US , pages 2261 - 2268, XP055866723, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.0c00395 *
ZHI-JIAN LI, ET. AL.: "Antifungal Activity of Gallic Acid In Vitro and In Vivo : Gallic acid; Candida albicans; Ergosterol ; CYP51; Mice", PHYTOTHERAPY RESEARCH, VOL. 31, N. 7, 1 July 2017 (2017-07-01), pages 1039 - 1045, XP055658098, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fptr.5823> [retrieved on 20200115], DOI: 10.1002/ptr.5823 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894424A (zh) * 2023-01-06 2023-04-04 中日友好医院(中日友好临床医学研究所) 新型双黄酮类化合物及其制备方法、药物组合物和应用
CN115894424B (zh) * 2023-01-06 2023-05-12 中日友好医院(中日友好临床医学研究所) 新型双黄酮类化合物及其制备方法、药物组合物和应用
WO2025082357A1 (fr) * 2023-10-16 2025-04-24 复旦大学 Composés polyphénoliques, leur procédé de préparation et leur utilisation

Also Published As

Publication number Publication date
KR20250002059A (ko) 2025-01-07

Similar Documents

Publication Publication Date Title
WO2020122360A1 (fr) Procédé de préparation d&#39;un extrait de zizania latifolia turcz. traité avec une enzyme présentant une teneur accrue en tricine, et composition de blanchissement, réduction des rides, anti-inflammatoire, antiallergique et d&#39;hydratation, préparée avec ce dernier
WO2015037891A1 (fr) Agent de blanchiment de la peau contenant un nouveau composé cyclique
WO2016076520A1 (fr) Composé pseudocéramide novateur et composition de préparation cutanée à usage externe le contenant
WO2021149880A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la croissance capillaire, comprenant, en tant que principe actif, un extrait mixte de concombre, d&#39;aubergine et d&#39;escargot
WO2017048028A1 (fr) Nouveau peptide antimicrobien dérivé du peptide myxinidine, et son utilisation
WO2021230677A1 (fr) Nouveau composé polyphénol et composition antifongique contenant celui-ci en tant que principe actif
WO2010123184A1 (fr) Composition pour prévenir et traiter l&#39;alopécie, à base de composés de norgalanthamine
WO2022231294A1 (fr) Composition destinée à prévenir, à atténuer ou à traiter la pigmentation de la peau
WO2014189347A1 (fr) Nouveau composé dérivé d&#39;une plante du genre quamoclit et composition le contenant comme principe actif pour la prévention ou le traitement du diabète
WO2020027534A1 (fr) Composition comprenant de la punicalagine permettant d&#39;inhiber l&#39;activité de par2
WO2015037855A1 (fr) Composition comprenant un extrait d&#39;herbes combinées comprenant de l&#39;acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2016093515A1 (fr) Composition pour activer un gène de longévité
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2021080297A1 (fr) Composition contenant un extrait de fleur d&#39;onagre en tant que principe actif pour prévenir ou traiter l&#39;obésité ou des syndromes métaboliques ainsi induits
WO2021261660A1 (fr) Procédé de préparation d&#39;extrait de farine d&#39;huile de sésame et composition alimentaire le comprenant en tant que principe actif pour la prévention ou le soulagement de la colite
WO2022164183A1 (fr) Composition pour favoriser la pousse des cheveux comprenant des vésicules extracellulaires dérivées de lactobacillus curvatus en tant que principe actif
WO2016159640A2 (fr) Composition anti-oxydante ou anti-vieillissement contenant du 5-adamantan-1-yl-n-(2,4-dihydroxybenzyl)-2,4-diméthoxybenzamide
WO2022255784A1 (fr) Vésicule dérivée de lactobacillus rhamnosus et ses utilisations
WO2020166868A1 (fr) Nanovésicules issues de bactéries du genre rothia et leur utilisation
WO2023101440A1 (fr) Composition anti-inflammatoire contenant un extrait de germe d&#39;arachide-nanoparticule d&#39;or en tant que principe actif
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
WO2012096463A2 (fr) Composition contenant un extrait végétal mélangé en tant que principe actif pour prévenir et améliorer une maladie de la peau allergique ou non allergique, et ses utilisations
WO2018155933A1 (fr) 6,7-diméthoxy-2,2-diméthyl-2h-chromène pour accroître l&#39;expression de l&#39;aquaporine-3 et son utilisation
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l&#39;obésité ou de syndromes métaboliques induits par cette dernière
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21805325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21805325

Country of ref document: EP

Kind code of ref document: A1